Yasmin’s work being published in European Journal of Immunology!

Proudly reporting that a significant part of Yasmin’s PhD work was recently published in the Eur. J. Immunol. Have a look at her work entitled “Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive” which informs on IL-10 co-expression in CAR-Treg cells providing an additional advantage to their intended suppressive capacity. Yasmin’s work provides an important proof-of-principle for this cell engineering approach for next-generation Treg therapy in transplantation.

Congratulations to Rainbow being awarded her PhD degree.

Rainbow’s viva happened already back in August, but now the Award has been confirmed after completion of all formalities. Rainbow’s project, co-supervised by Dr Gilbert Fruhwirth and Prof Ramón Vilar, focused on building a probe that allowed tumour imaging at a whole-body and microscopic level, while selectively delivering a highly cytotoxic agent into tumours.

Happy Rainbow with happy examiners right after the event – Congratulations to Rainbow and thanks to the examiners!

“A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma”

Proud to see our latest work published by the British Journal of Cancerhttps://lnkd.in/djxJhGQ.
We proposed a migrastatic drug development pipeline. As part of the pipeline, we provide a new traceable spontaneous melanoma metastasis model for in vivo quantification of metastasis and anti-metastatic effects by non-invasive imaging.

This was a fantastic team effort between Vicky Sanz Moreno‘s team at Barts Cancer Institute and ourselves at King’s College London – Massive THANKS to everybody involved!
#cancerresearch #metastasis #drugdiscovery #imaging #celltracking #skincancer

Options for imaging cellular therapeutics in vivo: a multi-stakeholder perspective

Sharing here a recent review we contributed to as part of an international consortium including the results of a multi-stakeholder survey by the HESI CT-TRACS Committee aimed at identifying areas of interest to help ensure the safe use of cellular therapeutics in the clinic.

Options for imaging cellular therapeutics in vivo: a multi-stakeholder perspective

We offer a brief overview of available technologies and then highlight the areas of interest from the survey by describing how imaging technologies can meet those needs. Areas of interest include imaging of cells over time, sensitivity of imaging modalities, ability to quantify cells, imaging cellular survival and differentiation, and safety concerns around adding imaging agents to cellular therapy protocols. 

#advancedtherapies #cellandgenetherapy #celltherapy #immunotherapy #celltracking #HESI #healthcare #emergingmarkets

Hot off the press: In vivo tracking of adoptively transferred regulatory T cells.

Through a great team effort we demonstrated quantitative non-invasive Treg tracking over weeks.

This addressed a fundamental need in Treg therapy development and offered a clinically compatible methodology for future Treg therapy imaging in humans.

Applying this approach, we also showed that Treg trafficking to skin grafts was regulated by the presence of recipient Gr-1+ innate immune cells.

Now available in Molecular Therapy – Methods Clinical Development

#celltherapy #transplantation #immunotherapy #imaging #molecularimaging